Yet, despite encouraging preclinical results in breast cancer models targeting HER2, MUC1, or mesothelin [7–9], single-target CAR-T cells have demonstrated minimal clinical efficacy in solid tumors, including breast cancer, with objective response rates below 13% [10]. This evidence concerns the gene ERBB2 and breast carcinoma.